Solara Active Pharma Sciences Ltd
Solara Active Pharma Sciences Ltd, headquartered in India, is a prominent player in the pharmaceutical industry, specialising in the development and manufacturing of active pharmaceutical ingredients (APIs) and intermediates. Founded in 2017, the company has quickly established itself as a key provider of high-quality products, catering to both domestic and international markets. With a focus on innovation and sustainability, Solara offers a diverse range of APIs, particularly in the therapeutic areas of anti-infectives, cardiovascular, and central nervous system medications. The company’s commitment to quality and regulatory compliance has earned it a strong market position, with notable achievements in securing approvals from major global regulatory bodies. Solara's strategic operational regions extend across Asia, Europe, and the Americas, reinforcing its status as a trusted partner in the pharmaceutical supply chain.
DitchCarbon Score
How does Solara Active Pharma Sciences Ltd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Solara Active Pharma Sciences Ltd's score of 0 is lower than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Solara Active Pharma Sciences Ltd's reported carbon emissions
In 2023, Solara Active Pharma Sciences Ltd reported total carbon emissions of approximately 11,168,000 kg CO2e for Scope 1 and about 43,425,000 kg CO2e for Scope 2. This represents a slight increase in Scope 1 emissions compared to 2022, which recorded about 10,169,000 kg CO2e, while Scope 2 emissions decreased from approximately 50,693,000 kg CO2e in the previous year. Looking ahead to 2024, the company anticipates a significant rise in emissions, with projected Scope 1 emissions reaching about 33,489,000 kg CO2e and Scope 2 emissions at approximately 43,622,000 kg CO2e. This increase in emissions highlights the challenges faced in reducing carbon footprints within the pharmaceutical industry. Despite these figures, Solara has not disclosed any specific reduction targets or initiatives as part of their climate commitments. The absence of documented reduction strategies suggests a need for enhanced focus on sustainability practices to align with industry standards and expectations for climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 10,169,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 50,693,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Solara Active Pharma Sciences Ltd is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
